The Bexion Story

2017

 

Bexion Pharmaceuticals completes Phase 1a of their First Clinical Trial.  Bexion receives the “Emerging Business” Award from LEAD Magazine and the Business Impact Award (Micro Business) from the Northern Kentucky Chamber of Commerce.

2016

Bexion Pharmaceuticals Receives FDA Clearance for the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer.

Bexion was awarded “Medical Professional Award” at the American Cancer Society’s Annual Strider’s Ball.

2015

Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme from FDA. Bexion wins a Tibbett’s Award by the Small Business Administration for exemplifying the very best in innovation.

2014

Bexion prepares IND for Phase 1

2013

Bexion wins prestigious $2.9MM NCI Bridge Award for Phase 1 in brain cancer

2012

BXQ-350 in IND-enabling studies in preparation for Phase 1 clinical studies

2011

Bexion held a very successful Pre-IND meeting with the FDA. Bexion plans to complete pre-tox animal studies and file IND with the FDA

2010

Bexion wins partnership with Nanotechnology Characterization Lab of NCI, and also $1.5MM NIH grant for brain cancer.

2009

Bexion wins grants to study brain, pancreatic and prostate cancer.

Bexion obtains Series A investment to fund efforts up to Phase 1 clinical study.

2006

Ray Takigiku, Ph.D. co-founds Bexion Pharmaceuticals; licenses anti-cancer technology from CCHMC

2004

Dr. Qi receives a small grant to study the protein on childhood cancer.

2002

Dr. Qi discovers that a protein involved in the inherited disease has anti-cancer properties.

1996

Xiaoyang Qi, Ph.D., a geneticist, joins CCHMC to find a cure for a rare inherited disease.